Drug labels would have to show where medications and ingredients were made
In committeeH.R. 8269Latest action
Sponsor: Richard McCormick · Representative · GA
AIDecoded by AI · checked against the recordRead the official text
Official title: CLEAR LABELS Act
119th Congress
Topics: Jobs & the economy
Introduced:
Read the official bill on Congress.govIn plain words
The plain-language version comes first. The official text is always the reference.
HR 8269 requires drug labels to identify manufacturers of active ingredients, finished products, and any packer or distributor involved.
60-second read · 4 questions answered below
What does this do?
HR 8269 would require prescription and over-the-counter drug labels to identify the original manufacturer of each active ingredient, the manufacturer of the finished drug product, and any packer or distributor involved. This information could appear directly on the label or be accessible through a barcode or QR code linked to an online database. Manufacturers would also have to provide this information in paper form upon request, and companies would have at least one year after FDA finalizes its rules to comply.
Who does it affect?
The bill affects drug manufacturers, packagers, and distributors that sell medications in the United States, including companies that source ingredients from overseas. Consumers and pharmacists would also be affected, gaining easier access to information about where a drug and its ingredients were produced.
Why does it matter?
People who want to know whether drug ingredients come from specific countries, such as China or India, where a large share of pharmaceutical ingredients are currently manufactured, would have a clearer way to find that information. The bill also exempts finished drug products that meet the new labeling requirements from a separate customs marking rule, since the drug label would already carry the required location information.
AI-drafted summary. Check it against the official text before you act on it.
Read the official bill on Congress.govMake the call
Where does it stand?
- IntroducedApr 14, 2026
- House committeeYou are here · Apr 14, 2026
- House vote
- Senate
- The president's desk
Right now: a House committee is reviewing it. If the Senate changes it, it goes back to the House before reaching the president.
Latest action: — Referred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
See how a call works
How it's being covered
Coverage of this bill from across the press. Each outlet's political lean is labeled where AllSides has rated it, and marked "Not rated" where it has not.
Newest of these articles:
Coverage of this bill so far comes from one side of the spectrum. Read it with that in mind.
truthout.org
Leans left
medpagetoday.com
Not rated
propublica.org
Center
Lean labels describe the news outlet, not this bill or any party. Ratings by AllSides.